In the News
Could a single pill crack the code of treating Alzheimer’s disease?
Fortune Magazine - Published by Onyx
Beginning a New Era of Precision Alzheimer’s Therapeutics
Inside Precision Medicine
Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc. January 2024
Newsweek Investment Reports
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s
Alzheimer's News Today
Press Releases
Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene
Valiltramiprosate Improved Cognition and Function in Prespecified Analysis in Patients at Mild Cognitive Impairment Stage
Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025
First Interventional Alzheimer’s Drug Trial Focused on High-Risk APOE4/4 Homozygotes with Major Unmet Medical Need for an Effective and Safe Treatment
Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon
Topline of APOLLOE4 Phase 3 Evaluating Valiltramiprosate/ALZ-801 Will be Presented at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025
Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors
Mr. Satter’s Extensive Investment, Company-Building, and Transaction Experience Strengthens Alzheon’s Board Leadership
New Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
APOLLOE4 is the first interventional AD drug trial focused on APOE4/4 homozygotes, a population enriched with amyloid pathology in brain parenchyma and small vessels – a condition called cerebral amyloid angiopathy
Alzheon to Present Phase 2 Biomarker Trial Results and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in Patients with Early Alzheimer’s Disease at Alzheimer’s Association International Conference
Fully Enrolled Pivotal APOLLOE4 Phase 3 Trial in Early Alzheimer’s Patients on Track for Topline Data Readout in 2024